Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?

Veracyte’s (VCYT) shares have surged 30.9% in the past year, showing impressive momentum. It has significantly outperformed the industry’s 13.1% decline and the S&P 500 composite’s 12.1% gain.  Presently carrying a Zacks Rank #3 (Hold), the global diagnostics company continues to benefit from the robust performance of Afirma and Decipher tests. Their solid future growth potential, along with strategic investment in the long-term growth drivers, is highly promising.Based in San Francisco, CA, Veracyte offers ...